Guangdong Jiaying Pharmaceutical Co., Ltd (SHE:002198)
China
· Delayed Price · Currency is CNY 5.84
-0.62 (-9.60%)
Apr 29, 2026, 3:04 PM CST
SHE:002198 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 383.75 | 375.41 | 533.03 | 659.03 | 574.28 | Upgrade
|
| Other Revenue | - | 0.76 | 0.2 | 0.17 | 0.44 | Upgrade
|
| Revenue | 383.75 | 376.17 | 533.23 | 659.2 | 574.71 | Upgrade
|
| Revenue Growth (YoY) | 2.02% | -29.45% | -19.11% | 14.70% | 5.50% | Upgrade
|
| Cost of Revenue | 153.73 | 151.91 | 186.34 | 229.22 | 143.26 | Upgrade
|
| Gross Profit | 230.02 | 224.25 | 346.9 | 429.98 | 431.45 | Upgrade
|
| Selling, General & Admin | 169.81 | 185.89 | 292.82 | 351.17 | 379.1 | Upgrade
|
| Research & Development | 9.04 | 6.76 | 10.1 | 15.34 | 14.4 | Upgrade
|
| Other Operating Expenses | 6.49 | 7.19 | 9.07 | 10.59 | 10.67 | Upgrade
|
| Operating Expenses | 185.34 | 203.88 | 311.34 | 379.76 | 402.16 | Upgrade
|
| Operating Income | 44.68 | 20.37 | 35.56 | 50.22 | 29.29 | Upgrade
|
| Interest Expense | - | -0 | -0 | -0.45 | -1.02 | Upgrade
|
| Interest & Investment Income | - | 2.08 | 2.7 | 2.74 | 3.67 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.28 | -0.02 | 0.01 | -0 | 1.48 | Upgrade
|
| EBT Excluding Unusual Items | 43.4 | 22.44 | 38.27 | 52.5 | 33.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.51 | - | 0.53 | 0.26 | -28.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.13 | 1.61 | 0.14 | -0.01 | -0.19 | Upgrade
|
| Asset Writedown | -3.8 | - | - | - | -0.01 | Upgrade
|
| Other Unusual Items | - | 1.05 | 0.44 | -1.65 | 1.39 | Upgrade
|
| Pretax Income | 37.95 | 25.1 | 39.37 | 51.1 | 5.82 | Upgrade
|
| Income Tax Expense | 7.47 | 4.48 | 5.05 | 7.16 | 4.35 | Upgrade
|
| Net Income | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 | Upgrade
|
| Net Income to Common | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 | Upgrade
|
| Net Income Growth | 47.87% | -39.94% | -21.88% | 2874.04% | -92.55% | Upgrade
|
| Shares Outstanding (Basic) | 507 | 508 | 508 | 507 | 509 | Upgrade
|
| Shares Outstanding (Diluted) | 507 | 508 | 508 | 507 | 509 | Upgrade
|
| Shares Change (YoY) | -0.11% | -0.00% | 0.07% | -0.41% | 0.40% | Upgrade
|
| EPS (Basic) | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 | Upgrade
|
| EPS Growth | 48.03% | -39.94% | -21.94% | 2886.21% | -92.58% | Upgrade
|
| Free Cash Flow | -100.92 | 22.14 | 93.39 | 24.41 | 49.46 | Upgrade
|
| Free Cash Flow Per Share | -0.20 | 0.04 | 0.18 | 0.05 | 0.10 | Upgrade
|
| Dividend Per Share | - | - | 0.050 | - | - | Upgrade
|
| Gross Margin | 59.94% | 59.61% | 65.05% | 65.23% | 75.07% | Upgrade
|
| Operating Margin | 11.64% | 5.42% | 6.67% | 7.62% | 5.10% | Upgrade
|
| Profit Margin | 7.94% | 5.48% | 6.44% | 6.67% | 0.26% | Upgrade
|
| Free Cash Flow Margin | -26.30% | 5.89% | 17.51% | 3.70% | 8.61% | Upgrade
|
| EBITDA | 65.97 | 39.92 | 59.77 | 76.11 | 57.69 | Upgrade
|
| EBITDA Margin | 17.19% | 10.61% | 11.21% | 11.55% | 10.04% | Upgrade
|
| D&A For EBITDA | 21.29 | 19.55 | 24.21 | 25.89 | 28.4 | Upgrade
|
| EBIT | 44.68 | 20.37 | 35.56 | 50.22 | 29.29 | Upgrade
|
| EBIT Margin | 11.64% | 5.42% | 6.67% | 7.62% | 5.10% | Upgrade
|
| Effective Tax Rate | 19.69% | 17.87% | 12.83% | 14.02% | 74.63% | Upgrade
|
| Revenue as Reported | - | 376.17 | 533.23 | 659.2 | 574.71 | Upgrade
|
| Advertising Expenses | - | 59.46 | 52.85 | 63.8 | 59.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.